Yeo Min-Kyung, Kim Jin-Man, Suh Kwang-Sun, Kim Seok-Hyung, Lee Ok-Jun, Kim Kyung-Hee
Department of Pathology, Cancer Research Institute, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Department of Pathology and Medical Science, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Transl Oncol. 2018 Feb;11(1):109-115. doi: 10.1016/j.tranon.2017.11.004. Epub 2017 Dec 18.
Partitioning defective (Par) proteins regulate cell polarity and differentiation. Par3, Par6β, and protein kinase Cζ (PKCζ), which are PAR complex members, have been shown to be associated with oncogenesis and progression. Herein, we report the expression pattern and clinical relevance of Par3, Par6β, and PKCζ in colorectal adenocarcinoma (CRAC). A total of 393 primary CRACs, 41 primary-metastatic CRAC pairs, 41 adenomas with low-grade dysplasia, and 41 nontumor colorectal tissue samples were examined by immunohistochemistry and Western blot assays for Par3, Par6β, and PKCζ protein expressions. The association Par3, Par6β, and PKCζ expressions and clinicopathologic factors, including patient survival, was evaluated. Primary CRACs and adenomas demonstrated higher levels of Par3, Par6β, and PKCζ than in nontumor colorectal epithelia. The expressions of Par3, Par6β, and PKCζ were higher in primary CRACs as compared to adenomas or in metastatic CRACs. Among primary CRACs, decreased Par3 expression was found to correlate with a high proliferation rate and poor histologic differentiation, decreased PKCζ expression was correlated with pathologic TNM stage (I-II vs III-IV) and lymph node metastasis, and decreased Par6β and PKCζ expressions were correlated with shortened overall survivals. In metastatic CRACs, decreased PKCζ expression was correlated with a shortened metastasis-free survival. While increased Par3, Par6β, and PKCζ expressions were implicated in tumorigenesis, decreased expressions of Par3, Par6β, and PKCζ were found to be associated with worse clinicopathologic factors in CRAC. In particular, the results of our study suggest that PKCζ down-expression is an independent poor prognostic and metastatic factor for CRAC.
分区缺陷(Par)蛋白调节细胞极性和分化。作为PAR复合物成员的Par3、Par6β和蛋白激酶Cζ(PKCζ)已被证明与肿瘤发生和进展相关。在此,我们报告Par3、Par6β和PKCζ在结直肠癌(CRAC)中的表达模式及临床相关性。通过免疫组织化学和蛋白质印迹分析,对总共393例原发性CRAC、41对原发性-转移性CRAC、41例低级别发育异常腺瘤以及41例非肿瘤性结直肠组织样本进行了Par3、Par6β和PKCζ蛋白表达检测。评估了Par3、Par6β和PKCζ表达与包括患者生存在内的临床病理因素之间的关联。原发性CRAC和腺瘤中Par3、Par6β和PKCζ的水平高于非肿瘤性结直肠上皮。与腺瘤相比,原发性CRAC中Par3、Par6β和PKCζ的表达更高,或者在转移性CRAC中更高。在原发性CRAC中,发现Par3表达降低与高增殖率和低组织学分化相关,PKCζ表达降低与病理TNM分期(I-II期与III-IV期)和淋巴结转移相关,Par6β和PKCζ表达降低与总生存期缩短相关。在转移性CRAC中,PKCζ表达降低与无转移生存期缩短相关。虽然Par3、Par6β和PKCζ表达增加与肿瘤发生有关,但在CRAC中发现Par3、Par6β和PKCζ表达降低与更差的临床病理因素相关。特别是,我们的研究结果表明PKCζ表达下调是CRAC的一个独立的不良预后和转移因素。